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Abstract
Background: Increasing resistance to quinolones and ceftriaxone in non typhoidal Salmonellae is a global concern. 
Resistance to quinolone and 3rd generation cephalosporin amongst non typhoidal Salmonellae (NTS) from Pakistan has 
been reported in this study.
Methods: Retrospective analysis of laboratory data was conducted (1990-2006). NTS were isolated and identified from 
clinical samples using standard microbiological techniques. Antimicrobial susceptibility testing was performed by Kirby 
Bauer. Extended spectrum beta lactamase production (ESBL) was detected using combined disc method. Ciprofloxacin 
sensitivity was detected by nalidixic acid screening method. Minimum inhibitory concentration (MIC) of ciprofloxacin 
was determined by agar dilution method. Statistical analysis was performed using SPSS version 13.
Results: Analysis of 1967 NTS isolates showed a significant increase in ciprofloxacin resistance from 23% in 2002 to 
50.5% in 2006, with increased mean MIC values from 0.6 to 1.3 ug/mL. Ceftriaxone resistant NTS also increased and 
ESBL production was seen in 98.7% isolates. These isolates exhibited high resistance against amoxicillin clavulanic acid 
(57%), gentamicin (69%), amikacin (44%) and piperacillin tazobactam (30%). No resistance to carbapenem was seen. 
Ceftriaxone resistance was significantly higher in children <1 year, in invasive isolates and in Salmonella Typhimurium.
Conclusions: Increase in quinolone and ceftriaxone NTS is a serious threat to public health requiring continuous 
surveillance and use of appropriate screening tests for laboratory detection.
Background
Non typhoidal salmonellae (NTS) are associated in
approximately 5% of the patients with bacteremia, inva-
sive infections and death [1]. Increased antimicrobial
resistance has made empiric antibiotic of choice for these
potentially fatal infections quite limited. Current litera-
ture recommends either a fluoroquinolones or a third
generation cephalosporins as drug of choice; however
increasing evidence of emergence of resistance against
these antibiotics in a great concern [2,3].
Outbreaks due to highly resistant NTS have been
reported from a number of countries [3-6]. Surveillance
of antimicrobial resistance amongst NTS is crucial, par-
ticularly in developing countries where facilities for cul-
ture and susceptibility testing are not widely accessible
and clinicians rely mainly on empirical therapy. While
increased resistance in typhoidal Salmonellae has been
reported from Pakistan, antimicrobial resistance data of
NTS is unavailable. Resistance to quinolone and 3rd gen-
eration cephalosporin with extended spectrum beta lac-
tamase (ESBL) producing NTS have not been yet
reported from this region. We have assessed antimicro-
bial susceptibility of NTS from Pakistan over a period of
17 years including analysis of resistance to quinolones
and 3rd generation cephalosporin.
Methods
Setting
This study was conducted from 1990-2006 at the Aga
Khan University (AKU), a tertiary care hospital in Kara-
chi, Pakistan. The hospital and laboratory are accredited
with Joint commission of international accreditation
(JCIA). Laboratory routinely participates in external
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quality control surveys with College of American pathol-
ogists (CAP). Clinical microbiology laboratory receives
specimens across the country via satellite centers in 50
major cities and towns of Pakistan. The data presented
here was not collected in a programmed survey but
obtained in routine analysis of specimens submitted to
the laboratory. All specimens although were processed in
laboratory based in Karachi but the data represents
strains prevalent across the country. This study was a ret-
rospective analysis of the laboratory data and did not
include any identifiable information from the patients
therefore formal ethical committee approval was not
obtained as per research guidelines of the institute.
Specimen Selection
Data including both invasive and non-invasive NTS was
retrieved from a central computerized database. Dupli-
cate specimens from same patients and samples with Sal-
monella enterica Typhi and Paratyphi were also excluded.
Microbiological Methods
During the study period NTS from stool and urine were
identified biochemically using conventional tests [7]. Iso-
lates from blood, tissues and other sterile body sites were
identified using API 20E (Bio Merieux France). Suspected
colonies were tested with Salmonella polyvalent antisera
(A-I and Vi) (Difco). Serogroups were determined using
the slide agglutination method. Non typeable Salmonella
spp. were those isolates that have biochemical (API 20E)
and serological profile suggestive of Salmonella but were
not further classified into serogroups due to limited avail-
ability of specific O antisera (only A, B, C and D). Sero-
types were determined by tube agglutination method
against H antigen. If an isolate was not serotyped with the
available H antisera only serogroups were reported.
Antimicrobial susceptibility testing was performed as
per Clinical Laboratory Standards Institute (CLSI) crite-
ria [8] against nalidixic acid (30 μg) ciprofloxacin (5 μg),
ampicillin (10 μg) ceftriaxone (30 μg), chloramphenicol
(30 μg), and cotrimoxazole (1.25/23.75 μg). ESBL produc-
tion was detected by combined disc method (ceftriaxone
alone and ceftriaxone-clavulanic acid) [8]. ESBL produc-
ing strains were further tested against amoxicillin-clavu-
lanic acid (20/10 μg), gentamicin (10 μg), amikacin (30
μg), piperacillin-tazobactam (100/10 μg) and meropenem
(10 μg). Since year 2002 susceptibility against ciprofloxa-
cin was determined by nalidixic acid screening method as
recommended by Hakanen et al [9]. Minimum inhibitory
concentrations against ciprofloxacin were determined
using agar dilution method [8]. Isolates that were resis-
tant to ampicillin, chloramphenicol and cotrimoxazole
were considered multidrug resistant (MDR).
Statistical Analysis
Clinical data were analyzed using SPSS version 15.0 soft-
ware. Comparisons were made between resistant and
sensitive strains in terms of age, gender, specimen source
and serogroups. Proportions were compared using the
Chi-square test or Fisher's exact test, where appropriate.
A p value of less than 5% was considered as statistically
significant.
Results
During the study period, a total of 1967 NTS were identi-
fied. A characteristic seasonal pattern in isolation of NTS
was observed with increased isolation in the months of
May-August corresponding with the summer and mon-
soon season (data not shown). Majority of NTS isolates
were from females (57.5%). Isolation rate of NTS was
higher in the age group under 5 years (55.5%). Out of
1967 isolates majority were from stool (91%) followed by
blood (6%). Most prevalent organisms were the Salmo-
nella group B (659) including Salmonella enterica Typh-
imurium (257) followed by Salmonella  group C (465),
Salmonella group A (62) and Salmonella group D (48).
Due to limited a vailability of a number of antisera the
large group of non-typeable Salmonella (728) could not
be speciated.
The resistance rates against nalidixic acid, ofloxacin
and ceftriaxone were increased (Fig. 1). This increase was
significant for nalidixic acid and ofloxacin (p value for
trend < 0.001). Between 1990 and 2001 in accordance
with NCCLS guidelines interpretative criteria of Enter-
obacteriaceae was used to report susceptibility of NTS
against fluoroquinolone, hence resistance was not
detected. However, following the introduction of nali-
dixic acid screening method in 2002, 27% of the NTS iso-
lates were noted to have reduced susceptibility to
quinolones. Mean MIC values of ofloxacin in NTS also
gradually increased during this period (Fig 2).
Ceftriaxone resistant NTS first observed in year 2000,
increased gradually over the years. ESBL production was
seen in 98.7% (n = 78) of ceftriaxone resistant NTS. ESBL
producing NTS isolates further showed resistance against
amoxicillin clavulanic acid (57%), gentamicin (69%), ami-
kacin (44%) and piperacillin/tazobactam (30%). Resis-
tance to carbapenem was not observed. Ceftriaxone
resistance was significantly higher (p value < 0.001)
amongst organisms isolated from patients less than 1 year
of age, in invasive isolates, in hospitalized patients and in
Salmonella enterica Typhimurium. In comparison to
other Salmonella spp., Salmonella enterica Typhimurium
had significantly higher resistance to ciprofloxacin (35.5
vs. 19%) and had higher MDR rate (39% vs. 8%).
Interestingly resistance against the first line drugs did
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phenicol decreased from 26% in 1990 to 7% in 2006 (p
value < 0.001). Similarly resistance against cotrimoxazole
and ampicillin remained static with minimum variations.
Isolation of MDR NTS strains significantly decreased to
3% in 2006 (p value < 0.001) (Fig 3).
Discussion
Globally empirical therapy of invasive NTS infections has
become challenging with the emergence of ceftriaxone
and quinolone resistance. This is the first report from
Pakistan reporting ESBL producing NTS isolates and
increase in quinolone. We also observed recent decline in
isolation of MDR NTS strains.
Since 1991 ceftriaxone resistant NTS has been reported
in various studies [6,10] and is reportedly mainly due to
ESBL (particularly CTX-M types) and AmpC β lactama-
ses [3,11]. Within our samples, ceftriaxone resistant NTS
were first isolated in the year 2000 and the rate of isola-
tion of these strains has gradually increased over the
years. 98.7% of our strains were ESBL producers and
showed concurrent resistance to broad spectrum antibi-
otics including amoxicillin-clavulanic acid, amikacin,
gentamicin and piperacillin-tazobactam. Fortunately car-
bapenem resistance, although reported previously in
NTS was not detected in our study [12]. The significant
association of these strains with patients under than 1
year of age and with invasive infections makes the man-
agement of these strains more problematic. Another con-
cern is inappropriate detection of such resistant strains in
most of the laboratories in Pakistan.
This study also reports an increase in fluoroquinolone
resistance from 23% in 2002 to 50.5% in 2006. Such an
increase is in agreement with reports from other coun-
tries [4,5]. Prior to 2002 we were using CLSI breakpoints
Figure 1 Showing marked increase in resistance against nalidixic acid, ofloxacin and ceftriaxone in NTS isolates at the Aga Khan University 
Hospital (1990-2006).
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recommended at the time and were therefore not able to
detect any resistance [8]. From 2002 onwards nalidixic
acid screening method was employed for the detection of
quinolone resistance. The rise in resistance rates corre-
lates also with increase in mean MIC values for these
strains. We recommend that accurate detection of Salmo-
nella strains with reduced quinolone susceptibility should
be reported by the clinical laboratories in Pakistan, as
clinical outcome with quinolones therapy is poor.
Salmonella Typhimurium had highest resistance rates
to ceftriaxone, ciprofloxacin and MDR. Increased resis-
tance to first line drugs has been reported previously in
Salmonella  Typhimurium from UK and Spain [13,14].
Another study from England and Wales has also reported
higher ceftriaxone resistance rates in this serotype [10].
Increased antimicrobial resistance in Salmonella Typh-
imurium is alarming as high mortality and invasive infec-
tions are associated with this serotype [15,16].
We also observed static resistance rates to ampicillin
and cotrimoxazole and a decline in resistance to chloram-
phenicol and MDR strains as reported previously in
Kenya [17]. Another report from Pakistan reporting
resistance rates in Salmonella Typhi also demonstrated
declining resistance to first line drugs [18]. They corre-
lated this with the overall antimicrobial consumption at
population level in Karachi and showed a steady reduc-
tion in the use of the above antibiotics especially
chloramphenicol. Based on their findings we can assume
similar correlation in NTS as well.
Conclusions
Increased resistance to ciprofloxacin and emergence of
ESBL producing NTS pose both diagnostic and manage-
ment dilemma in a developing country like Pakistan.
Measures should be taken to stop further emergence of
resistance and their dissemination on a priority basis.
Preventive strategy would require improved laboratory
services, continuous surveillance and restriction of use of
broad spectrum antibiotics.
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Figure 2 Showing gradual increase in ciprofloxacin MICs in NTS isolates at the Aga Khan University Hospital (2002-2006).
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Figure 3 Showing trends of resistance against first line drugs in NTS isolates at the Aga Khan University Hospital (1990-2006).
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